<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Int AIDS Soc</journal-id><journal-id journal-id-type="iso-abbrev">J Int AIDS Soc</journal-id><journal-id journal-id-type="publisher-id">JIAS</journal-id><journal-title-group><journal-title>Journal of the International AIDS Society</journal-title></journal-title-group><issn pub-type="epub">1758-2652</issn><publisher><publisher-name>International AIDS Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25397537</article-id><article-id pub-id-type="pmc">4225425</article-id><article-id pub-id-type="publisher-id">19793</article-id><article-id pub-id-type="doi">10.7448/IAS.17.4.19793</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Sessions &#x02013; Abstract P261</subject></subj-group></article-categories><title-group><article-title>Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-NNRTI subgroup analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Stellbrink</surname><given-names>Hans-Juergen</given-names></name><xref ref-type="aff" rid="AF0001_19793">1</xref></contrib><contrib contrib-type="author"><name><surname>Antinori</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="AF0002_19793">2</xref></contrib><contrib contrib-type="author"><name><surname>Pozniak</surname><given-names>Anton</given-names></name><xref ref-type="aff" rid="AF0003_19793">3</xref></contrib><contrib contrib-type="author"><name><surname>Flamm</surname><given-names>Jason</given-names></name><xref ref-type="aff" rid="AF0004_19793">4</xref></contrib><contrib contrib-type="author"><name><surname>Bredeek</surname><given-names>Fritz</given-names></name><xref ref-type="aff" rid="AF0005_19793">5</xref></contrib><contrib contrib-type="author"><name><surname>Patel</surname><given-names>Kiran</given-names></name><xref ref-type="aff" rid="AF0006_19793">6</xref></contrib><contrib contrib-type="author"><name><surname>Garner</surname><given-names>Will</given-names></name><xref ref-type="aff" rid="AF0006_19793">6</xref></contrib><contrib contrib-type="author"><name><surname>Piontkowsky</surname><given-names>David</given-names></name><xref ref-type="aff" rid="AF0006_19793">6</xref></contrib></contrib-group><aff id="AF0001_19793"><label>1</label>Infectious Diseases, ICH Study Center, Hamburg, Germany</aff><aff id="AF0002_19793"><label>2</label>Infectious Diseases, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani IRCCS, Rome, Italy</aff><aff id="AF0003_19793"><label>3</label>HIV Unit, St Stephens Centre, Chelsea and Westminster Hospital, London, UK</aff><aff id="AF0004_19793"><label>4</label>Infectious Diseases, Kaiser Permanente, Sacramento, CA, USA</aff><aff id="AF0005_19793"><label>5</label>HIV Medicine, Metropolis Medical Group, San Francisco, CA, USA</aff><aff id="AF0006_19793"><label>6</label>HIV Division, Gilead Sciences, Foster City, CA, USA</aff><pub-date pub-type="epub"><day>02</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>17</volume><issue>4Suppl 3</issue><elocation-id content-type="doi">19793</elocation-id><permissions><copyright-statement>&#x000a9; 2014 Stellbrink H-J et al; licensee International AIDS Society</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1_19793"><title>Introduction</title><p>Switch to Stribild (STB) was non-inferior to continuation of a non-nucleoside reverse transcriptase inhibitor (NNRTI) with emtricitabine and tenofovir DF (FTC/TDF) at week 48 in virologically suppressed HIV adults [<xref rid="CIT0001_19793" ref-type="bibr">1</xref>]. We report the Week 48 efficacy and safety of STB versus nevirapine (NVP) or rilpivirine (RPV) with FTC/TDF in suppressed subjects.</p></sec><sec id="st2_19793"><title>Materials and Methods</title><p>Virologically suppressed subjects on an NNRTI with FTC/TDF regimens for &#x02265;6 months were randomized (2:1) to switch to STB versus continue their NNRTI regimen. Eligibility criteria included no documented resistance to FTC and TDF, no history of virologic failure and eGFR &#x02265;70 mL/min. The primary endpoint was the proportion of subjects in the modified ITT population who maintained HIV-1 RNA &#x0003c;50 copies(c)/mL at Week 48 by FDA snapshot algorithm (12% non-inferiority margin). Subgroup analysis by non-EFV NNRTI use (NVP [74]; RPV [19]; etravirine [3]) at screening was pre-specified.</p></sec><sec id="st3_19793"><title>Results</title><p>The mITT population included 433 subjects who were randomized and treated. In the non-EFV NNRTI subgroup, 59 switched to STB; 37 continued a non-EFV NNRTI (27 NVP, 10 RPV) with FTC/TDF. At week 48, 97% STB versus 95% non-EFV NNRTI maintained HIV-1 RNA &#x0003c;50 c/mL. No emergent resistance was detected in either group. No difference in median increases from baseline in CD4 count at week 48 (cells/&#x000b5;L): 25 STB versus 55 non-EFV NNRTI (p=0.78). No discontinuation due to adverse events; no cases of proximal renal tubulopathy. As expected, there were no significant changes in the frequency of neuropsychiatric symptoms (i.e. anxiety, insomnia, dizziness, vivid dreams, weird/intense dreams, and nightmares) reported on the HIV Symptom Index at week 48 compared to baseline after switching to STB. There was a greater but non-progressive decrease from baseline in eGFR in the STB versus non-EFV NNRTI group; median changes (mL/min) at week 48: &#x02212;9.1 versus &#x02212;1.4. Switch to STB was associated with a higher treatment ease (convenience, flexibility, demand, lifestyle, understanding) score (range: &#x02212;15 to 15) at week 4 (median: 14 vs 11; p=0.047) and week 24 (median: 14 vs 12.5; p=0.038).</p></sec><sec id="st4_19793"><title>Conclusions</title><p>In this small group of virologically suppressed subjects, switch to STB vs continuation of NVP or RPV with FTC/TDF was safe, well-tolerated, and associated with a high rate of virologic suppression at week 48. There was more treatment ease with STB use.</p></sec></abstract></article-meta></front><back><ref-list><title>Reference</title><ref id="CIT0001_19793"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pozniak</surname><given-names>A</given-names></name><name><surname>Markowitz</surname><given-names>M</given-names></name><name><surname>Mills</surname><given-names>A</given-names></name><name><surname>Stellbrink</surname><given-names>HJ</given-names></name><name><surname>Antela</surname><given-names>A</given-names></name><name><surname>Domingo</surname><given-names>P</given-names></name><etal/></person-group><article-title>Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial</article-title><source>Lancet Infect Dis</source><year>2014</year><volume>14</volume><issue>7</issue><fpage>590</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">24908550</pub-id></element-citation></ref></ref-list></back></article>